Press release
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics - Pipeline Analysis 2018 | ArmaGen, Inc., JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics, Inc.
Download the sample report: https://www.pharmaproff.com/request-sample/1145
At birth, individuals with MPS II do not display any symptoms of the condition. Later, between the age of 2 to 4 years, features like full lips, large rounded cheeks, broad nose, and an enlarged tongue (macroglossia) are seen in them.
Get the detailed analysis at: https://www.pharmaproff.com/report/mps-ii-therapeutics-pipeline-analysis
The vocal cords also enlarge, which result in deep and hoarse voice. Narrowing of the airway causes frequent upper respiratory infections and short pauses in breathing during sleep (sleep apnea). As this disorder progresses, individuals need medical assistance to keep their airway open. Most people with this disorder develop hearing loss and have recurrent ear infections.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1145
The drug candidates of MPS II pipeline include, but are not limited to, AGT-182, JR-141 and SB-913. Further companies like ArmaGen Inc., JCR Pharmaceuticals Co. Ltd., and Sangamo Therapeutics Inc. are also involved in the pipeline for MPS II therapeutics.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Therapeutics - Pipeline Analysis 2018 | ArmaGen, Inc., JCR Pharmaceuticals Co Ltd, Sangamo Therapeutics, Inc. here
News-ID: 1715150 • Views: …
More Releases for MPS
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Modular Panelboard System (MPS) Market 2022 | Detailed Report
Global Modular Panelboard System (MPS) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5256552
The report…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Managed Print Services (MPS) Market Experience A Tremendous growth in future
HTF MI recently introduced Global Managed Print Services (MPS) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Xerox Corporation, HP, Canon, Ricoh, Lexmark, Konica Minolta Inc.,…
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom.
Led by…
Data8 to offer unlimited TPS, CTPS and MPS screening licences
Data8, the premier data enrichment specialist, have today announced that they will offer unlimited licenses to large volume TPS (Telephone Preference Service), CTPS (Corporate Telephone Preference Service) and MPS (Mail Preference Service) users. By removing the royalty fee structure, data8 believe it will encourage wide spread adoption by clients of these data files.
Antony Allen, managing director data8, “I am pleased to announce today that from 1st February 2012 we…
